跳转至内容
Merck
CN

A0152000

乙酰半胱氨酸杂质C

European Pharmacopoeia (EP) Reference Standard

别名:

N,N′-二乙酰基-L-胱氨酸, NSC 203780

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C10H16N2O6S2
化学文摘社编号:
分子量:
324.37
MDL number:
UNSPSC Code:
41116107
EC Number:
226-911-5
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

S(SCC(NC(=O)C)C(=O)O)CC(NC(=O)C)C(=O)O

InChI key

YTPQSLLEROSACP-UHFFFAOYSA-N

InChI

1S/C10H16N2O6S2/c1-5(13)11-7(9(15)16)3-19-20-4-8(10(17)18)12-6(2)14/h7-8H,3-4H2,1-2H3,(H,11,13)(H,12,14)(H,15,16)(H,17,18)

grade

pharmaceutical primary standard

API family

acetylcysteine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括 SDS 和任何产品信息小册子,均由药典颁发机构制定和发布。

如需进一步信息和支持,请访问现行药典网站。

Application

本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途,用户请自行负责。本标准品不适用于人类或动物使用。
用于制备参考溶液 (c),根据欧洲药典各论 0967,使用气相色谱法(通则 2.2.28)测试乙酰半胱氨酸中的相关物质。

Packaging

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

Other Notes

可能适用相应的销售限制。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Acetylcysteine
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 4900-4901 (2021)
Knut Pettersson et al.
Cardiovascular drug reviews, 21(2), 119-132 (2003-07-09)
Inflammatory processes in the arterial wall are important in atherogenesis. The present review discusses the development of DiNAC as a potential new treatment modality for atherosclerosis related diseases. DiNAC, N,N'-diacetyl-L-cystine, is the disulphide dimer of N-acetyl cysteine, NAC. It was
Knut S Pettersson et al.
Basic & clinical pharmacology & toxicology, 100(1), 36-42 (2007-01-12)
N,N-diacetyl-L-cystine (DiNAC), a novel immunomodulator, stimulates contact sensitivity/delayed type hypersensitivity reactions in mice induced by oxazolone and reduces atherosclerosis in Watanabe heritable hyperlipidaemic (WHHL) rabbits. Forty-week-old WHHL rabbits were given DiNAC (3 micromol/kg per day) for 8 weeks, and endothelium-mediated
S Böhler et al.
Infusionstherapie (Basel, Switzerland), 15(2), 89-92 (1988-04-01)
In this study the question of whether N-N-diacetylcystine (DAC), which is more stable than N-acetylcysteine (AcCYS), may provide a useful cysteine source for parenteral nutrition was investigated. In in vitro studies the release of cysteine from DAC was measured. The
S Boräng et al.
Gene, 271(2), 183-192 (2001-06-22)
In this study, we have applied and evaluated a modified cDNA representational difference analysis (RDA) protocol based on magnetic bead technology to study the molecular effects of a candidate drug (N,N'-diacetyl-L-cystine, DiNAC) in a model for atherosclerosis. Alterations in a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持